GALDERMA

EST. 1981

# GO BEYOND

## WITH ADVANCED PERFORMANCE

relfydess™

relabotulinumtoxinA


Designed with PEARL™ Technology: see results starting from Day 1, sustained through 6 months for up to 75% of patients, from a ready-to-use formulation.*†[1-3]

Step into the future of neuromodulation

FOR HEALTHCARE PROFESSIONALS ONLY.

Prescribing information and adverse events reporting information can be found on the back of this document.

This promotional material has been produced and funded by Galderma.

Not an actual patient. Relfydess™ is indicated for the temporary improvement in the appearance of moderate-to-severe glabellar lines (GLs) at maximum frown and moderate-to-severe lateral canthal lines (LCLs) at maximum smile in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.

# Are you ready to discover Relfydess™?

## ADVANCED PERFORMANCE[1]

Relfydess™ delivers fast results starting from Day 1, sustained through 6 months for up to 75% of patients.*†[1]

## HIGH LEVEL OF SATISFACTION

Relfydess™ provides a natural, revitalised look that patients are satisfied with and would recommend.[2-5]

## PIONEERING SIMPLICITY[1]

Designed for aesthetic use, Relfydess™ is a ready-to-use liquid neuromodulator optimised for simple volumetric dosing.

## NEW LEVEL OF PURITY

Relfydess™ is free of complexing protein and is free from human- or animal-derived components.[6,7]

# Relfydess™: Defining a new standard in neuromodulation

Elevate your patients' neuromodulator experience twice a year: Sustained results for GLs and LCLs, with up to **75% of patients maintaining improvements through 6 months.**[1]

There's no need to wait for natural-looking results: Fast onset for GLs and LCLs, with up to **39% of patients seeing effects from Day. 1**[1]

Designed for aesthetic use, introducing a **ready-to-use** liquid neuromodulator optimised for simple **volumetric dosing.**[1]

# Elevate your patients' neuromodulator experience twice a year with fast and sustained results*†[1-3]

*Up to* 75% maintained improvements through **6 months**†[1-3]

*Up to* 39% saw effects from **Day 1***[1-3]

At 6 months, more than half of patients agreed the treatment effects of Relfydess™ **lasted longer** than their previous neuromodulator treatments.‡[8]

## BEFORE AND AFTER RELFYDESS™ TREATMENT

Patient treated with Relfydess™ for GLs and LCLs

FROWNING



Baseline | Day 1 | Month 1 | Month 4

Before and after images for illustrative purposes only.
Individual results may vary. All rights reserved.
Permission sought to use patient's images.

# PEARL™ Technology: The breakthrough behind Relfydess™

**Starting with a proprietary strain, PEARL™ Technology is designed to optimise activity and purity for a highly active formulation containing only the essentials.§6,7**

## GALDERMA-QUALITY *FROM START TO FINISH*[9]

The proprietary bacterial strain gives Galderma complete control of the manufacturing process.[9]

PEARL™ TECHNOLOGY by GALDERMA

## STARTS LIQUID, *STAYS LIQUID*[10]

Designed to preserve the potency and original form of the core molecule.[10]

## GENTLE, *BY DESIGN*[10]

Carefully removes complexing proteins and impurities, keeping only the essentials.§10¼

# Discover the next generation of neuromodulation with a formulation optimised for simple volumetric dosing[1,10]

***Simple volumetric dosing*[1,10]**
1 unit = 0.01 mL = 1 mark on the syringe**[1]




***No complex calculations*[1,10]**
Simply draw up and inject the required volume[1]

***Convenient and consistent dosing, every vial, every time*[1,10]**
No risk of reconstitution-related errors or contamination[1,10]

***Reduces preparation time and waste*[1,11*]**
Supports practice efficiency[11]

*Based off of previous studies with liquid neuromodulators

# Help your patients maintain that mirror moment feeling with a natural, revitalised look they'd recommend[4,5,10]

*Up to* 98%

would **return** for treatment and **recommend** Relfydess™ after 1 month, with up to 90% agreeing through 6 months[††5,10]

>90%

agreed they looked **natural** when making expressions after 1 month[‡‡2,3]

Relfydess™ has a **demonstrated safety profile** with a low incidence of treatment-related adverse events over repeated visits, in line with in-market neuromodulators.[§§2,3,10,12-15]

## BEFORE AND AFTER RELFYDESS™ TREATMENT

Patient treated with Relfydess™ for GLs and LCLs

SMILING



Baseline | Day 1 | Month 1 | Month 4

The future of neuromodulation is here, so why wait?

# Prescribing Information

Please click here for Relfydess™ prescribing information and adverse event reporting information.

**GL,** glabellar line; **LCL,** lateral canthal line; **U,** unit(s).

* 39% of patients treated for GLs (n=223) and 34% of patients treated for LCLs (n=230) with Relfydess™ saw an onset of effect by Day 1, as estimated from a Kaplan-Meier analysis of patient diary card response for the first seven days following treatment in the two READY-1 and READY-2 Phase III multicentre, randomised, double-blind, placebo-controlled studies evaluating the efficacy and safety of a single dose of Relfydess™ for the treatment of moderate-to-severe GLs (READY-1; N=300) or LCLs (READY-2; N=303) over 6 months. Median time to onset was two days.[1-3]

† 75% of patients treated for GLs (n=212) and 64% of patients treated for LCLs (n=189) with Relfydess™ did not return to baseline within 6 months, as estimated from a Kaplan-Meier analysis of time to return to baseline severity on both investigator and patient scales in the READY-1 and -2 studies.[1-3]

‡ Based on the Subject Treatment Questionnaire from the RELAX Phase IIIb multicentre, randomised, double-blind, placebo-controlled study evaluating aesthetic improvement and onset of effect after a single dose of Relfydess™ for the treatment of moderate-to-severe GLs (N=132) over 12 months. At the 6-month visit, 53% of patients treated with Relfydess™ agreed or strongly agreed with the statement 'The treatment effects from the study product last longer than the treatment effects from previous neuromodulators' (n=99).[8]

§ Relfydess™ is complexing protein-free and is free from human- or animal-derived components.[10]

** With most standard syringes.

†† Based on the Facial Lines Treatment Satisfaction Questionnaire from the READY-1 and -2 studies. 98% (GLs, n=218) and 93% (LCLs, n=226) of patients treated with Relfydess™ at Month 1 and 90% (GLs, n=210) and 86% (LCLs, n=223) at Month 6 agreed or strongly agreed with the statement 'I would have this treatment done again'. 98% (GLs) and 93% (LCLs) at Month 1 and 90% (GLs) and 88% (LCLs) at Month 6 agreed or strongly agreed with the statement 'I would recommend this treatment to others'.[2,3]

‡‡ Based on the Natural Expressions Questionnaire from the READY-1 and -2 studies. 94% (GLs, n=218) and 91% (LCLs, n=226) of patients treated with Relfydess™ agreed or strongly agreed with the statement 'I look natural when I make expressions'.[1,2]

§§ Approved for use in Australia, Canada, Europe, and/or the United States.[16-19]

**1.** Galderma. Relfydess Summary of Product Characteristics. 2024. **2.** Galderma Laboratories. MA-47072. Clinical Study Report for Protocol 43QM1602: READY-1. Fort Worth, TX: 2021. **3.** Galderma Laboratories. MA-47073. Clinical Study Report for Protocol 43QM1901: READY-2. Fort Worth, TX: 2021. **4.** Galderma Laboratories. MA-47072. Clinical Study Report for Protocol 43QM1602: READY-1. Tables 14.02.11.04 and 14.02.12.02. Fort Worth, TX: 2021. **5.** Galderma Laboratories. MA-47073. Clinical Study Report for Protocol 43QM1901: READY-2. Tables 14.2.12.4 and 14.2.13.2. Fort Worth, TX: 2021. **6.** Do M, et al. Poster presented at: TOXINS 2022 Conference; New Orleans, US; July 27–30, 2022. **7.** Sundberg AL, Stahl U. Poster presented at: TOXINS 2021 Virtual Conference; January 16–17, 2021. **8.** Galderma Laboratories. MA-59692. Clinical Study Report for Protocol 43QM2106: RELAX. Fort Worth, TX: 2023. **9.** Galderma. Data on file. MA-55945. MI Letter RelabotulinumtoxinA strain. September 2023. **10.** Shridharani SM, et al. Aesthet Surg J. 2024 June. [Epub ahead of print]. doi: 10.1093/asj/sjae131. **11.** Chadha P, et al. J Cosmet Dermatol. 2024 May. [Epub ahead of print]. doi: 10.1111/jocd.16359. **12.** Galderma Laboratories. MA-47074. Clinical Study Report for Protocol 43QM1902: READY-3. Fort Worth, TX: 2022. **13.** Galderma Laboratories. MA-48067. Clinical Study Report for Protocol 43QM1903: READY-4. Fort Worth, TX: 2021.14. Galderma Laboratories. MA-59104. Clinical Study Report for Protocol 43QM2107. EXPRESSION. Fort Worth, TX: 2024. **14.** Galderma Laboratories. MA-59104. Clinical Study Report for Protocol 43QM2107. EXPRESSION. Fort Worth, TX: 2024. **15.** Cavallini M, et al. Dermatol Surg. 2014;40:525–36. **16.** medsinfo.com.au. Available at: https://medsinfo.com.au. Date accessed: November 2024. **17.** Government of Canada. Drug Product Database. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html. Date accessed: November 2024. **18.** Electronic Medicines Compendium. Browse active ingredients A-Z. Available at: https://www.medicines.org.uk/emc/browse-ingredients. Date accessed: November 2024. **19.** U.S. Food & Drug Administration. National Drug Code Directory. Available at: https://dps.fda.gov/ndc. Date accessed: November 2024.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

GALDERMA

EST. 1981

UKI-REL-2500062 | DOP April 2025